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Idiopathic pulmonary ﬁbrosis (IPF) is a dreaded disease of uncertain etiology and no available cure. It is
still unclear if a causal relationship exists between gastro-esophageal reﬂux (GER) and IPF, but studies
have shown an increased prevalence of acid reﬂux in patients with IPF. We describe a patient with
achalasia and GER who went on to develop IPF. She underwent a rapidly worsening course punctuated by
acute exacerbations of IPF, despite best efforts to manage the acid GER. We also reviewed the literature
on the role of GER in the etiology and progression of IPF and the impact of antireﬂux measures on its
course.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a progressive disease with
a steady downhill course, despite a variety of treatment strategies.
Gastro-esophageal reﬂux (GER) is known to occur in a high pro-
portion of patients with IPF. We describe a patient with IPF whose
disease progression was drastically altered by GER.2. Case
A 54 year old female with a history of celiac disease was on
treatment with proton pump inhibitors (PPI) for her new onset of
reﬂux symptoms. Upper gastrointestinal endoscopy was unre-
markable. Esophageal manometry and motility studies revealed a
hypertensive lower esophageal sphincter with mild esophageal
dysmotility, suggestive of achalasia. PPIs were continued on a twice
daily basis. She also received endoscopic injections of botulinum
toxin in the lower esophageal sphincter (LES) with partial andMedicine, Yale-New Haven
York Street, New Haven, CT
dithan).
Ltd. This is an open access article utransient relief of symptoms. Six months following the onset of her
reﬂux symptoms, she developed slowly progressive shortness of
breath and cough. A chest radiograph showed bilateral interstitial
thickening. A high-resolution computed tomography (CT) of the
chest revealed a bilateral prominent interstitial reticular pattern
predominantly in the lower lobes and subpleural regions with mild
honeycombing (Fig. 1), consistent with IPF. Pulmonary function
tests (PFTs) showed an FVC of 61%, FEV1 of 64% and FEV1/FVC of
106% suggestive of a restrictive pattern. Total lung capacity and vital
capacity were diminished, the residual volume to total lung ca-
pacity ratio was elevated at 122% and the diffusion capacity for
carbon monoxide was diminished at 39%. Video assisted thoraco-
scopic lung biopsy showed chronic active interstitial pneumonitis
and ﬁbrosis with maximal changes beneath the pleura. Histopa-
thology demonstrated a usual interstitial pneumonia (UIP) pattern,
corresponding to the clinical diagnosis of IPF (Fig. 2). PPIs were
continued and she also followed the lifestyle changes advised for
GER. She was placed on a trial of N-acetyl cysteine without obvious
beneﬁt.
Over the next year, while stable symptomatically, PFTs showed a
gradual decline in lung volumes, forced vital capacity and diffusion
capacity. In the next few months, she developed progressive
worsening shortness of breath. A repeat CT of the chestnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. On initial evaluation, high resolution computed tomography of the chest shows
bilateral interstitial reticular pattern on the lower lobes with mild honey combing.
Fig. 2. Video assisted thoracoscopic lung biopsy showed chronic active interstitial
pneumonitis and ﬁbrosis representing usual interstitial pneumonia pattern.
Fig. 3. Repeat high resolution computed tomography of the chest done for worsening
symptoms reveals increasing ﬁbrosis and traction bronchiectasis.
Fig. 4. Double contrast barium swallow done 3 months following laparoscopic Heller's
myotomy with fundoplication shows persistent dilatation at the region of
fundoplication.
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bronchiectasis (Fig. 3). Since she also had progressive reﬂux
symptoms despite medical treatment, she underwent a laparo-
scopic Heller's myotomy (LHM) with Dor fundoplication. In the
next three months her reﬂux symptoms worsened, and she dete-
riorated with severe shortness of breath and hypoxia, requiring
continuous nasal oxygen. A double contrast barium swallow
revealed no evidence of a leak and persistent dilatation at the re-
gion of fundoplication (Fig. 4). Gastric emptying studies showed no
delay. Repeat imaging revealed severe extensive honey combing
and air trapping with superimposed ground glassing (Fig. 5). Her
respiratory status continued to decline and she died of respiratory
failure.3. Discussion
IPF is a devastating disease with a progressive downhill course.
It has a serious impact on the quality of life and carries a mediansurvival rate of only 3e5 years [1]. Despite the burden imposed by
IPF on health care and numerous clinical trials with several agents,
with an absence to date of a clear etiopathogenesis there has been
no improvement in mortality. Research recently focuses on alveolar
epithelial injury resulting in an exaggerated tissue reaction and
ﬁbrosis [2]. There is growing consensus on the role of chronic
asymptomatic microaspiration causing the initial insult, resulting
in aberrant wound healing. Animal models have demonstrated that
aspiration of gastric ﬂuid can result in activation of the ﬁbrosis
cascade in the pulmonary parenchyma through increased concen-
tration of proﬁbrotic and inﬂammatory cytokines IL-1, IL-2, TNF-
alpha and TGF-beta [3]. Though similar studies are not possible in
humans, there has beenmuch emphasis in the association between
IPF and GER, which is the most important risk factor for micro-
aspiration. Esophageal 24-h pH monitoring has shown abnormal
esophageal acid exposure in 68e94% of patients with IPF [4e6],
Fig. 5. Computed tomography of the chest done 3 months after the surgery reveals
extensive honey combing and ground glassing indicating superimposed pneumonitis.
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controls and the general population. Many of these patients did not
have the classical clinical symptoms of reﬂux, and standard dose
PPI therapymay not suppress the acid GER in this group. The role of
non-acid reﬂux and chronic micro-aspiration of gastric contents
has also been studied in these patients. Bronchoalveolar lavage
(BAL) pepsin, which has been proven to be a good biomarker for
gastric aspiration in several population subsets, was found to be
elevated in patients with IPF when compared to the general pop-
ulation. Also, BAL pepsin levels have been found to be signiﬁcantly
higher in patients with acute exacerbation when compared to the
stable cohort of IPF patients, which suggests that aspiration plays
an important part in the progression of the disease by causing acute
exacerbations [7].
Though an association between GER and IPF is proven, it is
difﬁcult to establish a cause-effect relationship. Gastro-esophageal
reﬂux disease (GERD) is very common in the general population,
and it is unclear why only a very small proportion develops pul-
monary ﬁbrosis. One argument against the causal relationship is
that increased reﬂux of gastric contents may be secondary to the
mechanical effects of IPF including poor lung compliance, distor-
tion of mediastinal anatomy and weakening of the lower esopha-
geal sphincter [8]. In a sizeable proportion of patients, the course of
IPF is characterised by periods of clinical stability interspersed with
acute exacerbations, which result in a decline of respiratory status
and worsen the clinical outcome of the disease [9]. GER and aspi-
ration are proposed mechanisms for these exacerbations, though
the exact cause remains unknown [10].
The case described above not only reinforces the postulated role
of GER in the progression of IPF, but also underlines the fact that
reﬂux can exacerbate IPF and contribute to accelerated deteriora-
tion of respiratory function. Our patient was onmedical therapy for
GERD. Since she had an anatomical abnormality in the form of
achalasia that predisposed her to acid reﬂux, laparoscopic Dor
fundoplication was done. However the surgery failed to correct the
reﬂux in her case and she continued to decline. Very few studies on
the effect of acid suppression therapy in IPF are available in the
literature. A case series on four patients with IPF and GER showed
that treatment of acid GER with PPI therapy can stabilize pulmo-
nary functions and prevent exacerbations [11]. Another retrospec-
tive study concluded that the use of medications for GER was
associated with reduced radiological ﬁbrosis and increased survival
in patients with IPF [12]. A recent study made an interestingobservation that patients with IPF whowere on anti-acid treatment
had a smaller decline in FVCwhen compared to thosewhowere not
[13]. Peri-operative data from a lung transplant center showed that
laparoscopic Nissen fundoplication and laparoscopic Dor fundo-
plication were associated with reduced episodes of acute rejection
after transplant and improvement in lung functions [14]. Another
case series on IPF patients awaiting lung transplantation demon-
strated stabilization of oxygen requirements with laparoscopic
Nissen fundoplication [15]. There are no studies directly comparing
anti-acid pharmacotherapy and anti-reﬂux surgery in patients with
IPF. Most of the support in favor of the use of PPIs in IPF patients is
based on the fact that acid suppression can reduce the stimulus for
further ﬁbrosis by limiting lung damage and that these agents are
much less expensive and toxic than the other agents available for
the management of the disease. However given the chronicity of
IPF, this also means that anti-acid treatment has to be used for a
long duration, which is fraught with risks. Long term use of PPIs has
been shown to increase the risk of enteric infections, especially
Clostridium difﬁcile and hospital-acquired pneumonia [16e18]. It is
also questionable if they would address the inﬂuence of non-acid
reﬂux reﬂux in the progression of the disease.
In conclusion, GER has a high prevalence in patients with IPF and
may be associated with the pathogenesis and progression of the
latter. Clinical symptoms of reﬂux are poor predictors of GER in this
population and hence there should be a low threshold to investi-
gate and treat them for reﬂux. The exact subset of patients who
need to be treated and the optimal acid suppression therapy in
patients with IPF that can prevent disease progression is not clear.
Also, the data on the efﬁcacy of anti-reﬂux surgery in patients with
IPF is yet to be clariﬁed.
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